DOCSLIB.ORG

Advanced Sterilization Products Alpharma Pharmaceuticals

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Manufacturers/Wholesalers Street City ST Zip Abbott Diabetes Care Abbott Diagnostic Division Abbott Laboratories 100 Abbott Park Rd. Bldg. AP6D-1 Abbott Park IL 60064 Abbott Molecular Abbott Nutrition Abbott Pharmaceutical Products Group Abbott Point of Care Abbott Spine Abbott Vascular Abraxis Bioscience, LLC. 11755 Wilshire Blvd., Suite 2000 Los Angeles CA 90025 Access Diabetic Supply, LLC Acorda Therapeutics, Inc. 15 Skyline Drive Hawthorne NY 10532 Actelion Pharmaceuticals US, Inc. 5000 Shoreline Court, Suite 200 S. San Francisco CA 94080 Advanced Medical Optics, Inc. 1700 E. St. Andrew Place Santa Anna CA 92705 Advanced Neuromodulation Systems, Inc. Advanced Sterilization Products 33 Technology Drive Irvine CA 92618 Agencourt Bioscience Corporation Alcon Laboratories, Inc. 6201 South Freeway Fort Worth TX 76134 Alexion Pharmaceuticals, Inc. 352 Knotter Drive Cheshire CT 06410 Alkermes, Inc. 88 Sidney Street Cambridge MA 02139 Allergan American, LLC. Allergan Holdings, Inc, Allergan Puerto Rico Holdings, Inc. Allergan Sales Allergan Sales Puerto Rico, Inc. Allergan Specialty Therapeutics, Inc. Allergan USA, Inc. Allergan, Inc. 2525 Dupont Drive Irvine CA 92612 Allscripts, LLC. 2401 Commerce Drive Libertyville IL 60048 Alpharma Pharmaceuticals, LLC 1 New England Ave Piscataway NJ 08854 American Medical System, Inc 10700 Bren Road West Minnetonka MN 55343 Ameridose, LLC. 50 Fountain Street Framingham MA 01702 Amgen, Inc. One Amgen Center Drive Thousand Oaks CA 91320 Amgen, USA AMO Sales and Service, Inc. Amphastar Pharmaceuticals, Inc. 11570 Sixth St. Rancho Cucamnga CA 91730 AMS- AMS Innovation Center 3070 Orchard Drive San Jose CA 95134 AMS Sales Corporation 10700 Bren Road West Minnetonka MN 55343 Amylin Pharmaceutical, Inc. 9360 Towne Center Drive San Diego CA 92121 Anda Pharmaceuticals, Inc. 6500 Adelaide Court Groveport OH 43125 Anda, Inc. 2915 Weston Road Weston FL 33333 APP Pharmaceuticals, LLC. 1501 East Woodfield Road, Suite 300E Schaumburg IL 60173 Apria Healthcare, Inc 26220 Enterprise Court Lake Forest CA 92630 Arizant Heathcare Inc. 10393 West 70th Street Eden Prairie MN 55344 Manufacturers/Wholesalers Street City ST Zip Arizant Inc Armstrong Pharmaceuticals, Inc. 10 Dan Rd. Canton MA 02132 Artes Medical, Inc. 5870 Pacific Center Blvd. San Diego CA 92121 Ascend Therapeutics, Inc. 607 Herndon Parkway, Suite 110 Herndon VA 20170 Astellas Pharma US, Inc. Three Parkway North Deerfield IL 60015 AstraZenca LP 1800 Concord Pike Wilmington DE 19850 Atto BioScience, Inc. Auburn Pharmaceutical 1775 John R. Road Troy MI 48083 Autosuture Auxilium Pharmaceuticals, Inc. 40 Valley Steam Parkway Malvern PA 19355 Avent, Inc. Axcan Pharma US, Inc. 22 Inverness Center Parkway Birmingham AL 35242 Ballard Medical Products Bard Access Systems, Inc. Bard Peripheral Vascular, Inc. Barr Pharmaceuticals, Inc. 225 Summit Avenue Montvale NJ 07645 Bausch & Lomb, Incorporated One Bausch & Lomb Place Rochester NY 14604 Baxter Healthcare Corporation One Baxter Parkway Deerfield IL 60015 Bayer Healthcare Pharmaceuticals, Inc. Bayer Healthcare, LLC. 555 White Plains Road Tarrytown NY 10591 Bayer Healthcare, LLC. Animal Health Division BD AcuteCare, Inc. BD Biosciences Sys & Reagents, Inc. BD Infusion Therapy Systems, Inc. BDI Pharma, Inc. 120 Research Drive Columbia SC 29203 Beckman Coulter, Inc. 4300 N Harbour Blvd. Fullerton CA 92835 Becton Dickinson and Company 1 Becton Drive Franklin Lakes NJ 07417 BEMS Holdings, LLC Bioform Medical, Inc. 1875 S. Grant St., Suite 110 San Mateo CA 94402 Biogen Idec 14 Cambridge Center Cambridge MA 02142 BioMarin Pharmaceutical, Inc. 105 Digital Drive Novato CA 94949 BioRx 10828 Kenwood Road Cincinnati OH 45242 Biosense Webster, Inc. 3333 Diamond Canyon Road Diamond Bar CA 91765 Boehringer Ingelheim Pharmaceuticals, Inc. 900 Ridgebury Rd. Ridgefield CT 06877 Boston Scientific Corporation One Boston Scientific Place Natick MA 01760 Boston Scientific Neuromodulation Corporation One Boston Scientific Place Natick MA 01760 BoundTree Medical, LLC Bristol-Myers Squibb Company Route 206 and Province Line Road Princeton NJ 08543 C.R. Bard, Inc. 730 Central Avenue Hill NJ 07974 Cardinal Companies (All Cardinal Health companies doing business in NV) Cardinal Health, Inc. 7000 Cardinal Place Dublin OH 43017 Carestream Health Inc. 150 Verona Street Rochester NY 14608 Celegene Corportation 86 Morris Avenue Summit NJ 07901 Centocor, Inc. Manufacturers/Wholesalers Street City ST Zip Centric Health Resources, Inc. 17879 Chesterfield Airport Rd. Chesterfield MO 63005 Cephalon, Inc. 41 Moores Frazer PA 19355 CLS Behring 1020 First Ave., PO Box 60501 King of Prussia PA 19406 Codman & Shurtleff, Inc. 325 Paramount Drive Raynham MA 02769 Collagenex Pharmaceuticals, Inc. Coram Alternate Site Services, Inc. Coram Healthcare Corporation of Northern California Coram Healthcare Corporation of Utah CoramRx, LLC Cordis Corporation 14201 NW 60th Avenue Miami Lakes FL 33014 Cordis Neurovascular, Inc. Coria Laboratories, LTD. 3909 Hulen Street Fort Worth TX 76107 Corum Healthcare Corporation of Nevada CoTherix, Inc. CovaTec 100 Healdquarters Park Drive Skillman NJ Covidien 15 Hampshire St. Mansfield MA 02048 Cubist Pharmaceuticals, Inc. 65 Hayden Avenue Lexington MA 02421 CUI Corporation Cumberland Pharmaceuticals, Inc. 2525 West End Avenue, suite 950 Nashville TN 37203 CV Therapeutics, Inc. 3172 Porter Drive Palo Alto CA 94304 Cynacon/OcuSoft dba Cypress Medical Products, LLC Daiichi-Sankyo Two Hilton Court Parsippany NJ 07054 Darby Dental Supply Inc. 300 Jericho Quadrangle Jericho NY 11753 Darby Dental Supply Inc. 4745 Longley Lane Reno NV 89502 Darby Dental Supply Inc. 4460 E. Holmes Road Memphis TN 38118 Davol, Inc. DePuy Miltek, Inc. 325 Paramount Drive Raynham MA 02768 DePuy Spine 325 Paramount Drive Raynham MA 02767 Dermik Laboratories Dey, LP Diagnostic Systems Laboratories, Inc. Direct Dental 1267 Spice Island Sparks NV 89431 Discovery Labware, Inc. Dispensing Solutions, Inc. 3000 W. Warner Ave. Santa Anna CA 92704 DJO Surgical DJO, LLC 1430 Decision St. Vista CA 92081 Dubin Medical, Inc. 970 Turquoise Street San Diego CA 92109 DuPuy Orthopedics, Inc. 700 Orthopaedic Drive Warsaw IN 46581 Duramed Pharmaceuticals, Inc. Eisai Corporation of North America 100 Tice Blvd. Woodcliff Lake NJ 07677 Eisai, Inc. Eithicon Endo-Surgery, Inc. 4545 Creek Road Cincinnati OH 45242 Elan Pharmaceuticals, Inc. 800 Gateway Blvd. S. San Francisco CA 94080 Manufacturers/Wholesalers Street City ST Zip Eli Lilly and Company Lilly Corporate Center Indianapolis IN 46285 EMD Lexigen, Inc. EMD Pharmaceuticals, Inc. EMD Serono Research Institute, Inc. EMD Serono, Inc. One Technology Place Rockland MA 02370 Emergency Medical Products, Inc. Empi Endo Pharmaceuticals, Inc. 100 Endo Blvd. Chadds Ford PA 19317 Enzon Pharmaceuticals, Inc. 685 Rt. 202/206 Bridgewater NJ 08807 Espirt Pharma Holding Company, Inc. Espirt Pharmac, Inc. Ethicon Inc., subsidary of Johnson and Johnson PO Box 151; Route 22 West Somerville NJ 08876 Expert Med Eyeonics, Inc. Eyetech, Inc. Falcon Pharmaceuticals, Ltd. FFF Enterprises, Inc. 41093 County Center Dr. Temecula CA 92591 FineTech Pharmaceutical, LTD. 33 Hanarkissim Str., PO Box 2015 Nesher, Israel 36608 First Veterinary Supply Fleming & Company, Pharmaceuticals dba Fleming Pharmaceuticals 1733 Gilsinn Lane Fenton MO 63026 Flowmatrix Corporation Forest Pharmaceuticals, Inc. 13600 Shoreline Dr. St. Louis MO 63045 Galderma Laboratories, L.P. 14501 North Freeway Fort Worth TX 76166 Gallipot, Inc. 2400 Pilot Knob Road St. Paul MN 55120 Gambro Renal Products, Inc. 14143 Denver West Parkway Lakewood CO 80401 Gate Pharmaceuticals GE Healthcare, Inc. 101 Carnegie Center Princeton NJ 08540 GeneOhm Sciences, Inc. General Injectables and Vaccines, Inc (GIV) Genetech, Inc. 1 DNA Way South San Francisco CA 94080 Genetech, USA, Inc. GenTrac, Inc. Genzyme Corporation 500 Kendall St. Cambridge MA 02142 Gilead Sciences, Inc. 333 Lakeside Drive Foster City CA 94404 Graham-Field, Inc. 2935 Northeast Pkwy. Atlanta GA 30360 Guidant Sales Corporation 4100 Hamline Avenue, North F368 St. Paul MN 55112 Gulf South Medical Supply H.D. Smith Wholesale Drug Co. 950 Lively Blvd. Wood Dale IL 601891 H.D. Smith Wholesale Drug/Barnes 1370 Victoria Stree Carson CA 90746 H.J. Harkins Company, Inc. dba Pharma Pac 513 Sandydale Drive Nipomo CA 93444 Hand Innovations, LLC. Healthpoint, LTD. 3909 Hulen Street Fort Worth TX 76107 Henry Schein 135 Duryea Rd. Melville NY 11747 Herbert Laboratories Manufacturers/Wholesalers Street City ST Zip Hoffman-La Roche, Inc. 340 Kingsland Street Nutley NJ 07110 Hospira, Inc. 275 North Field Drive Lake Forest IL 60045 Ikara, Inc. Inamed Corporation Inamed Development Company Inamed International Corp. Inamed, LLC. Independent Pharmacy Cooperative 1550 Columbus St. Sun Prairie WI 53590 Influence Medical Technologies Ltd. 10700 Bren Road West Minnetonka MN 55343 InnovaQuartz Incorporated dba American Medical Systems and AMS 23030 N. 15th Ave. Phoenix AZ 85027 INO Therapeutics, LLC 6 Route 173 Clinton NJ 08809 InSource, Inc. Integra LifeSciences Holdings Corporation 311 Enterprise Drive Plainsboro NJ 08536 Intendis, Inc. International Medication Systems, Ltd. 1886 Santa Anita Ave. S. El Monte CA 91733 Janssen Jazz Pharmaceuticals, Inc. 3180 Porter Drive Palo Alto CA 94304 JMI-Daniels Pharmaceuticals, Inc. Johnson & Johnson Healthcare Products Division of Mxceil, PPC, Inc. 199 Grandview Road Skillman NJ 08558 Johnson & Johnson-Merck Consumer Pharmaceuticals Co. 7050 Camp Hill Road Ft. Washington PA 19034 Johnson and Johnson Consumer
Recommended publications
  • 2009: Turning the Corner

    2009: Turning the Corner

    data page 2009: Turning the corner Walter Yang Despite the shaky start to 2009, the biotech sector regained its financial Although initial public offerings showed signs of resuscitation (at least footing. Biotech indices were up, as were offerings and partnership mon- 13 more companies are now in the queue), follow-on financings came in ies. Excluding collaborations, the sector raised a total of $24.3 billion. above $6 billion—the second-best year over the past decade. Stock market performance Global biotech industry financing Although biotech indices were up ~16% last year, they underperformed The boost in partnership promises to US biotechs and follow-on financings other major indices. pushed industry funding to $61.3 billion, up 82% from 2008. 1,500 Swiss Market S&P 500 2009 36.9 10.0 5.1 2.2 6.0 0.9 1,400 NASDAQ Biotech Dow Jones 2008 20.0 3.2 5.3 3.1 1.9 0.1 1,300 NASDAQ BioCentury 100 2007 22.4 11.7 6.8 4.7 4.4 3.0 1,200 Partnering 2006 19.8 11.9 5.6 4.7 5.6 2.0 1,100 Year Debt and other Index 17.3 6.1 5.4 2.7 4.8 1.9 1,000 2005 Venture capital PIPEs 900 2004 10.9 8.8 5.3 2.9 3.3 2.6 Follow-ons 800 2003 8.9 9.1 4.0 2.2 3.9 0.5 IPOs 700 010203040506070 Amount raised ($ billions) 1/09 2/09 3/09 4/09 5/09 6/09 7/09 8/09 9/09 12/08 Month ending 10/09 11/09 12/09 Partnership figures are for deals involving a US company.
  • Appendix a 2016 Financial Report Financial Review Pfizer Inc

    Appendix a 2016 Financial Report Financial Review Pfizer Inc

    Appendix A 2016 Financial Report Financial Review Pfizer Inc. and Subsidiary Companies GLOSSARY OF DEFINED TERMS Unless the context requires otherwise, references to “Pfizer,” “the Company,” “we,” “us” or “our” in this 2016 Financial Report (defined below) refer to Pfizer Inc. and its subsidiaries. We also have used several other terms in this 2016 Financial Report, most of which are explained or defined below: 2016 Financial Report This Financial Report for the fiscal year ended December 31, 2016, which was filed as Exhibit 13 to the Annual Report on Form 10-K for the fiscal year ended December 31, 2016 2016 Form 10-K Annual Report on Form 10-K for the fiscal year ended December 31, 2016 AAV Adeno-Associated Virus ABO Accumulated postretirement benefit obligation ACA (Also referred to as U.S. U.S. Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Healthcare Legislation) Act. ACIP Advisory Committee on Immunization Practices ALK anaplastic lymphoma kinase Allergan Allergan plc Alliance revenues Revenues from alliance agreements under which we co-promote products discovered or developed by other companies or us AM-Pharma AM-Pharma B.V. Anacor Anacor Pharmaceuticals, Inc. Astellas Astellas Pharma U.S. Inc. ASU Accounting Standards Update ATM-AVI aztreonam-avibactam Bamboo Bamboo Therapeutics, Inc. Baxter Baxter International Inc. BMS Bristol-Myers Squibb Company CDC U.S. Centers for Disease Control and Prevention Cellectis Cellectis SA Celltrion Celltrion Inc. and Celltrion Healthcare,
  • [Docket No. FDA-2017-N-3203] Wyeth Pharmaceutical

    [Docket No. FDA-2017-N-3203] Wyeth Pharmaceutical

    This document is scheduled to be published in the Federal Register on 06/21/2017 and available online at https://federalregister.gov/d/2017-12908, and on FDsys.gov 4164-01-P DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. FDA-2017-N-3203] Wyeth Pharmaceuticals Inc. et al.; Withdrawal of Approval of 121 New Drug Applications and 161 Abbreviated New Drug Applications AGENCY: Food and Drug Administration, HHS. ACTION: Notice. SUMMARY: The Food and Drug Administration (FDA) is withdrawing approval of 121 new drug applications (NDAs) and 161 abbreviated new drug applications (ANDAs) from multiple applicants. The holders of the applications notified the Agency in writing that the drug products were no longer marketed and requested that the approval of the applications be withdrawn. DATES: The withdrawal is effective on [INSERT DATE 30 DAYS AFTER DATE OF PUBLICATION IN THE FEDERAL REGISTER]. FOR FURTHER INFORMATION CONTACT: Florine P. Purdie, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 51, rm. 6248, Silver Spring, MD 20993-0002, 301-796-3601. SUPPLEMENTARY INFORMATION: The holders of the applications listed in table 1 in this document have informed FDA that these drug products are no longer marketed and have requested that FDA withdraw approval of the applications under the process in § 314.150(c) (21 CFR 314.150(c)). The applicants have also, by their requests, waived their opportunity for a hearing. Withdrawal of approval of an application or abbreviated application under § 314.150(c) is without prejudice to refiling. 2 Table 1 Application No.
  • OSI Pharmaceuticals and AVEO Pharmaceuticals Expand Oncology Discovery and Translational Research Collaboration

    OSI Pharmaceuticals and AVEO Pharmaceuticals Expand Oncology Discovery and Translational Research Collaboration

    OSI Pharmaceuticals and AVEO Pharmaceuticals Expand Oncology Discovery and Translational Research Collaboration July 21, 2009 9:24 PM ET MELVILLE, NY and CAMBRIDGE, Mass., July 21, 2009 – OSI Pharmaceuticals, Inc. (NASDAQ:OSIP) and AVEO Pharmaceuticals, Inc. today announced that they have expanded the drug discovery and translational research collaboration announced in October of 2007. The alliance is anchored around developing molecular targeted therapies to target the underlying mechanisms of epithelial-mesenchymal transition (EMT) in cancer and to develop proprietary datasets of associated patient selection biomarkers to support OSI’s targeted medicine pipeline. EMT is a process of emerging significance in tumor development and disease progression and the focal point of OSI’s proprietary oncology research efforts. The companies are expanding their efforts to validate cancer targets and to deploy key elements of AVEO’s proprietary translational research platform in support of OSI’s clinical development programs. Under the terms of the expanded discovery and research agreement, OSI will pay AVEO a total of $20 million at closing, $5 million of which is an upfront cash payment and $15 million of which is the purchase of additional equity in AVEO. OSI will also provide AVEO research funding over the next two years to support the collaboration, and the potential to achieve additional royalties and milestones. In return, OSI will immediately receive rights beyond the original collaboration including rights to additional EMT targets (including up to 4 antibody targets) and increased access to AVEO technology (i.e. tumor models, archives and biomarkers). OSI is also acquiring non-exclusive access to AVEO’s proprietary bioinformatics platform.
  • Overview of Ftc Antitrust Actions in Pharmaceutical Services and Products

    Overview of Ftc Antitrust Actions in Pharmaceutical Services and Products

    OVERVIEW OF FTC ANTITRUST ACTIONS IN PHARMACEUTICAL SERVICES AND PRODUCTS Health Care Division Bureau of Competition Federal Trade Commission Washington D.C. 20580 Markus H. Meier Assistant Director Bradley S. Albert Deputy Assistant Director Saralisa C. Brau Deputy Assistant Director September 2009 TABLE OF CONTENTS Page I. INTRODUCTION. ........................................................... 1 II. CONDUCT INVOLVING PHARMACEUTICAL SERVICES AND PRODUCTS. 3 A. Monopolization. ...................................................... 3 B. Agreements Not to Compete. ............................................ 8 C. Agreements on Price or Price-Related Terms. 14 D. Agreements to Obstruct Innovative Forms of Health Care Delivery or Financing. 20 E. Illegal Tying and Other Arrangements. .................................... 20 III. PHARMACEUTICAL MERGERS. ........................................... 20 A. Horizontal Mergers Between Direct Competitors. 20 B. Potential Competition Mergers. ......................................... 44 C. Innovation Market Mergers. ............................................ 47 D. Vertical Mergers...................................................... 49 IV. INDUSTRY GUIDANCE STATEMENTS...................................... 50 A. Advisory Opinions. ................................................... 50 B. Citizen Petition to the Food and Drug Administration. 51 V. AMICUS BRIEFS. ......................................................... 51 VI. INDICES. ............................................................
  • IPR2016-01284 Patent 6,900,221 B1 ______

    IPR2016-01284 Patent 6,900,221 B1 ______

    [email protected] Paper No. 49 571.272.7822 Filed: January 8, 2018 UNITED STATES PATENT AND TRADEMARK OFFICE ____________________ BEFORE THE PATENT TRIAL AND APPEAL BOARD ____________________ APOTEX INC., APOTEX CORP., APOTEX PHARMACEUTICALS HOLDINGS INC., AND APOTEX HOLDINGS, INC., Petitioner, v. OSI PHARMACEUTICALS LLC, Patent Owner. ____________________ Case IPR2016-01284 Patent 6,900,221 B1 ____________ Before LORA M. GREEN, RAMA G. ELLURU, and ZHENYU YANG, Administrative Patent Judges. GREEN, Administrative Patent Judge. FINAL WRITTEN DECISION Determining That Claims 44‒46 and 53 Are Shown to Be Unpatentable 35 U.S.C. § 318(a) and 37 C.F.R. § 42.73 IPR2016-01284 Patent 6,900,221 B1 I. INTRODUCTION Apotex Inc., Apotex Corp., Apotex Pharmaceuticals Holdings Inc., and Apotex Holdings, Inc., (“Apotex” or “Petitioner”) filed a Petition requesting an inter partes review of claims 44–47 and 53 of U.S. Patent No. 6,900,221 B1 (Ex. 1001, “the ’221 patent”). Paper 3 (“Pet.”). OSI Pharmaceuticals LLC1 (“OSI” or “Patent Owner”) filed a Preliminary Response to the Petition.2 Paper 7 (“Prelim. Resp.”). We determined that the information presented in the Petition and the Preliminary Response demonstrated that there was a reasonable likelihood that Petitioner would prevail in challenging claims 44–47 and 53 as unpatentable under 35 U.S.C. § 103(a). Pursuant to 35 U.S.C. § 314, we instituted trial on January 9, 2017, as to all of the challenged claims of the ’221 patent. Paper 8 (“Institution Decision” or “Dec. Inst.”). On February 8, 2017, the parties filed a Joint Motion to Limit Petition Under 37 C.F.R.
  • Amgen 2008 Annual Report and Financial Summary Pioneering Science Delivers Vital Medicines

    Amgen 2008 Annual Report and Financial Summary Pioneering Science Delivers Vital Medicines

    Amgen 2008 Annual Report and Financial Summary Pioneering science delivers vital medicines About Amgen Products Amgen discovers, develops, manufactures Aranesp® (darbepoetin alfa) and delivers innovative human therapeutics. ® A biotechnology pioneer since 1980, Amgen Enbrel (etanercept) was one of the fi rst companies to realize ® the new science’s promise by bringing EPOGEN (Epoetin alfa) safe and effective medicines from the lab Neulasta® (pegfi lgrastim) to the manufacturing plant to patients. NEUPOGEN® (Filgrastim) Amgen therapeutics have changed the practice of medicine, helping millions of Nplate® (romiplostim) people around the world in the fi ght against ® cancer, kidney disease, rheumatoid Sensipar (cinacalcet) arthritis and other serious illnesses, and so Vectibix® (panitumumab) far, more than 15 million patients worldwide have been treated with Amgen products. With a broad and deep pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people’s lives. 0405 06 07 08 0405 06 07 08 0405 06 07 08 0405 06 07 08 Total revenues “Adjusted” earnings Cash fl ow from “Adjusted” research and ($ in millions) per share (EPS)* operations development (R&D) expenses* (Diluted) ($ in millions) ($ in millions) 2008 $15,003 2008 $4.55 2008 $5,988 2008 $2,910 2007 14,771 2007 4.29 2007 5,401 2007 3,064 2006 14,268 2006 3.90 2006 5,389 2006 3,191 2005 12,430 2005 3.20 2005 4,911 2005 2,302 2004 10,550 2004 2.40 2004 3,697 2004 1,996 * “ Adjusted” EPS and “adjusted” R&D expenses are non-GAAP fi nancial measures. See page 8 for reconciliations of these non-GAAP fi nancial measures to U.S.
  • Manufacturers with Signed Rebate Agreements February 1 , 2011

    Manufacturers with Signed Rebate Agreements February 1 , 2011

    Wisconsin Medicaid Pharmacy Data Table Manufacturers with Signed Rebate Agreements February 1 , 2011 NEWLABELER NAME START END SC NEW LABELER NAME START END SC 00002 ELI LILLY AND COMPANY 1/1/1991 Y 00126 COLGATE ORAL PHARMACEUTICAL 1/1/1991 Y 00003 E R SQUIBB AND SONS INC. 1/1/1991 Y 00131 SCHWARZ PHARMA, INC. 1/1/1991 Y 00004 HOFFMANN LAROCHE INC 1/1/1991 00132 C B FLEET COMPANY INC. 1/1/1991 00005 LEDERLE LABORATORIES 1/1/1991 Y 00135 SMITHKLINE BEECHAM 1/1/1995 Y 00006 MERCK SHARP & DOHME 1/1/1991 Y 00143 WEST-WARD PHARMACEUTICAL C 1/1/1991 Y 00007 SMITHKLINE BEECHAM CORPORATI 1/1/1991 Y 00145 STIEFEL LABORATORIES INC. 1/1/1991 Y 00008 WYETH AYERST LABORATORIES 1/1/1991 Y 00149 PROCTER & GAMBLE PHARMACEU 1/1/1991 Y 00009 PHARMACIA AND UPJOHN 1/1/1991 Y 00168 E FOUGERA AND CO, DIV OF ALTAN 1/1/1991 Y 00013 PHARMACIA AND UPJOHN 1/1/1991 Y 00169 NOVO NORDISK PHARMACEUTICAL 1/1/1991 Y 00015 INVAMED, INC 1/1/1991 Y 00172 ZENITH LABORATORIES, INC 1/1/1991 Y 00023 ALLERGAN INC. 1/1/1991 Y 00173 GLAXOSMITHKLINE 1/1/1991 Y 00024 SANOFI SYNTHELABO 1/1/1991 Y 00178 MISSION PHARMACAL COMPANY 1/1/1991 Y 00025 PHARMACIA CORPORATION 1/1/1991 Y 00182 GOLDLINE LABORATORIES INC 1/1/1991 Y 00026 BAYER CORP PHARMACEUTICAL DI 1/1/1991 Y 00185 EON LABS MANUFACTURING, INC. 1/1/1991 Y 00028 NOVARTIS PHARMACEUTICALS 1/1/1991 Y 00186 ASTRAZENECA LP 1/1/1991 Y 00029 SMITHKLINE BEECHAM CORPORATI 1/1/1991 Y 00187 ICN PHARMACEUTICALS INC.
  • AILERON THERAPEUTICS, INC. (Name of Registrant As Specified in Its Charter)

    AILERON THERAPEUTICS, INC. (Name of Registrant As Specified in Its Charter)

    Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material Pursuant to §240.14a-12 AILERON THERAPEUTICS, INC. (Name of Registrant as Specified in Its Charter) (Name of Person(s) Filing Proxy Statement, if Other Than the Registrant) Payment of Filing Fee (Check the appropriate box): ☒ No fee required. ☐ Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11. (1) Title of each class of securities to which transaction applies: (2) Aggregate number of securities to which transaction applies: (3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined): (4) Proposed maximum aggregate value of transaction: (5) Total fee paid: ☐ Fee paid previously with preliminary materials. ☐ Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing. (1) Amount previously paid: (2) Form, Schedule or Registration Statement No.: (3) Filing Party: (4) Date Filed: Table of Contents AILERON THERAPEUTICS, INC.

  • Reporter's Handbook

    2O14 RE POR TER’ S HANDBOOK for the biopharmaceutical research industry Member Companies 1 Research Associates 2 U.S. Health-Related Trade and Professional Organizations 3 Government Medical and Health Contacts 4 Voluntary Health Agencies 5 International Pharmaceutical Associations/Health Care Groups 6 Key Facts/About PhRMA 7 Company Products by Category 8 Member Companies 1 Member Companies Abbott Dept 383, AP6D 100 Abbott Park Road Abbott Park, IL 60064-3500 Phone: (847) 937-6100 Fax: (847) 937-1511 Website: www.abbott.com Melissa Brotz, Corporate Public Affairs Office: (847) 935-3456 E-Mail: [email protected] Kelly Morrison, Corporate Public Affairs, Science/Policy Office: (847) 937-3802 E-Mail: [email protected] Scott Stoffel, Corporate Public Affairs, Financial Office: (847) 936-9502 E-Mail: [email protected] Steve Chesterman, Medical Optics Office: (714) 247-8711 E-Mail: [email protected] Jonathon Hamilton, Vascular Devices 3200 Lakeside Drive, Suite 355 Santa Clara, CA 95054 Office: (408) 845-3491 E-Mail: [email protected] AbbVie 1 North Waukegan Road North Chicago, IL 60064 Phone: (847) 932-7900 Website: www.abbvie.com Gulden Mesara, Vice President, Global Commercial and Health Communications Office: (847) 938-2804 E-Mail: [email protected] Angela Sekston, Vice President, Leadership and Employee Communications Office: (847) 937-6636 E-Mail: [email protected] Morry Smulevitz, Head of U.S. Public Affairs Office: (847) 937-2152 E-Mail: [email protected] 1-1
  • UNITED STATES SECURITIES and EXCHANGE COMMISSION Form

    UNITED STATES SECURITIES and EXCHANGE COMMISSION Form

    Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 Form 10-K (Mark One) ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF ☒ 1934 For the fiscal year ended December 31, 2008 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT ☐ OF 1934 Commission file number 000-12477 Amgen Inc. (Exact name of registrant as specified in its charter) Delaware 95-3540776 (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) One Amgen Center Drive, 91320-1799 Thousand Oaks, California (Zip Code) (Address of principal executive offices) (805) 447-1000 (Registrant’s telephone number, including area code) Securities registered pursuant to Section 12(g) of the Act: Common stock, $0.0001 par value; preferred share purchase rights (Title of class) Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☒ No ☐ Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No ☒ Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or Section 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐ Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K.
  • In the United States District Court for the District of Delaware

    In the United States District Court for the District of Delaware

    Case 1:15-cv-01063-UNA Document 1 Filed 11/17/15 Page 1 of 17 PageID #: 1 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE OSI PHARMACEUTICALS, LLC, PFIZER ) INC., and GENENTECH, INC., ) ) Plaintiffs, ) ) v. ) C.A. No. ) BRECKENRIDGE PHARMACEUTICAL, ) INC. and NATCO PHARMA LTD., ) ) Defendants. ) COMPLAINT FOR PATENT INFRINGEMENT Plaintiffs OSI Pharmaceuticals, LLC (“OSI”), Pfizer Inc. (“Pfizer”) and Genentech, Inc. (“Genentech”) (collectively, “Plaintiffs”), by their undersigned attorneys, bring this action against Defendant Breckenridge Pharmaceutical Inc., (“Breckenridge”), and Natco Pharma Ltd. (“Natco”) (collectively, “Breckenridge/Natco”) for patent infringement and allege as follows: NATURE OF THE ACTION 1. This is an action for patent infringement under the patent laws of the United States, Title 35 of the United States Code, the Federal Food, Drug, and Cosmetic Act, Title 21 of the United States Code, and the Declaratory Judgment Act, 28 U.S.C. §§ 2201 et seq., arising from Breckenridge/Natco’s filing of an Abbreviated New Drug Application No. 208488 (“Breckenridge/Natco ANDA” or “ANDA No. 208488”) with the United States Food and Drug Administration (“FDA”) seeking approval to commercially market generic versions of TARCEVA® (“Breckenridge/Natco’s Proposed Generic Products”) prior to the expiration of certain patents that relate to that product, United States Reissued Patent No. RE 41,065 (“the RE ‘065 patent”), and United States Patent No. 6,900,221 (“the ‘221 patent”). Case 1:15-cv-01063-UNA Document 1 Filed 11/17/15 Page 2 of 17 PageID #: 2 THE PARTIES 2. Plaintiff OSI is a limited liability company organized and existing under the laws of the State of Delaware, with a principal place of business at 1 Astellas Way, Northbrook, IL 60062.